NEW research published in the American Journal of Respiratory and Critical Care Medicine has confirmed an association, not necessarily causative, between the use of Chantix (in Australia Champix, generic name varenicline) and cardiac events.
The study involved data on 56,851 new varenicline users, who were observed from one year before to one year after varenicline use, prompting authors to say that "the risks should be weighed against the benefit of the drug for individual patients".
The same study looked at an association with neuropsychiatric events, but "this was found to be of questionable clinical significance and was not robust in sensitivity analyses" - atsjournals.org.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Feb 18
